You are here

Phase 3 Protocol for Oxymorphone Approved

CHADDS FORD, Pa., Nov. 22 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP - News), today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the protocol relating to its developmental product, oxymorphone extended-release tablets (oxymorphone ER), under the FDA's Special Protocol Assessment (SPA) process.

"We are pleased by the FDA's decision, which clears the way for us to begin enrolling patients in this clinical trial," said Carol A. Ammon, chairman and chief executive officer. "We now believe we will be in a position to file our complete response to the FDA's approvable letter for oxymorphone ER in early 2006."

Under the terms of the SPA, Endo will conduct a 12-week, multicenter, double-blinded, placebo-controlled Phase III trial of oxymorphone ER in patients who have had no prior or recent treatment with opioid analgesics.

Source: Endo Pharmaceuticals, Inc.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients